Coronavirus BRIEFING
Supported by Essilor

The Latest COVID-19 Data

The National Average for Gross Revenue at ECP Locations Remained Flat for the Week of April 1–7, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Wednesday, April 10, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations remained flat last week, April 1–7, when compared with the previous week. That places gross revenue at a level -1 index point below where it was at this point in time (Week 14) when compared with last year (2023), 3 points above the same period in 2022, 10 points above 2021, 103 points above 2020 and 16 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

For Some MDs, Long COVID Burnout Is a New Reality

By Staff
Monday, April 8, 2024 8:02 AM Dhaval Desai, MD, was teaching his 4-year-old to ride a bike after another exhausting shift at the hospital during the summer after the first COVID-19 surge. He was putting on a happy face and forcing out a "Yay!" he did not feel. The pandemic had taken its toll, and he just wanted to lie down and be alone. Realizing that he was "scraping to find joy" was when he knew something was wrong.

Study Shows Nirmatrelvir–Ritonavir No More Effective Than Placebo for COVID-19 Symptom Relief

By Staff
Monday, April 8, 2024 8:02 AM Paxlovid does not significantly alleviate symptoms of COVID-19 compared with placebo among nonhospitalized adults, a new study published on April 3 in The New England Journal of Medicine found.

How Therapy Can Help During Life-Changing Events Like COVID

By Staff
Thursday, April 4, 2024 7:59 AM When the COVID-19 pandemic hit 4 years ago, Jenn Kearney felt extra thankful for her years of therapy. The 34-year-old digital communications manager from Boston said her 11 years of doing therapy, specifically cognitive behavioral therapy, or CBT, prior to the pandemic had given her skills and “ways to cope and adapt that not only benefited me, but the people around me,” she said.

Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients

By Staff
Thursday, April 4, 2024 6:09 AM Nirmatrelvir/ritonavir (Paxlovid) failed to shorten COVID-19 symptom duration among people at standard risk for severe COVID-19 and among vaccinated people with at least one risk factor for severe disease, according to final results of the phase II/III EPIC-SR.

The National Average for Gross Revenue at ECP Locations Decreased for the Week of March 25–31, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Wednesday, April 3, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations decreased last week, March 25–31, when compared with the previous week at a rate of -4 index points. That places gross revenue at a level -1 index point below where it was at this point in time (Week 13) when compared with last year (2023), 2 points above the same period in 2022, 4 points above 2021, 97 points above 2020 and 14 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

Latest COVID Vax Cuts Hospitalization Risk in Immunocompromised People

By Staff
Tuesday, April 2, 2024 6:12 AM For adults who are immunocompromised, the updated 2023-2024 COVID-19 vaccine reduced risk of hospitalization compared with not getting the shot, according to CDC data.

Pediatric Mental Health Was Stable Early in the Pandemic

By Staff
Friday, March 29, 2024 8:02 AM The mental health of children and adolescents was largely stable during the first year of the COVID-19 pandemic, but racial disparities in access to outpatient psychiatric care worsened, new research suggested.

Fauci: When Confronted With Misinformation, Stick to the Science

By Staff
Friday, March 29, 2024 6:15 AM While public health professionals don't get formal training on how to operate in highly politically charged and divisive environments, the best thing to do is stick to the facts, evidence, and data, Anthony Fauci, MD, former director of the National Institute of Allergy and Infectious Diseases (NIAID), told an audience of health policy graduate students on Wednesday.

New Data: Long COVID Cases Surge

By Staff
Thursday, March 28, 2024 8:02 AM Experts worry a recent rise in long COVID cases—fueled by a spike in winter holiday infections and a decline in masking and other measures—could continue into this year.

Health Workers Fear Profits May Trump Safety in New CDC Recommendations

By Staff
Wednesday, March 27, 2024 8:02 AM Four years after hospitals in New York City overflowed with COVID-19 patients, emergency physician Sonya Stokes remains shaken by how unprepared and misguided the American health system was.

The National Average for Gross Revenue at ECP Locations Increased for the Week of March 18–24, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Wednesday, March 27, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations increased last week, March 18–24, when compared with the previous week at a rate of 1 index point. That places gross revenue at a level 5 index points above where it was at this point in time (Week 12) when compared with last year (2023), 11 points above the same period in 2022, 6 points above 2021, 54 points above 2020 (the first week of COVID lockdown restrictions) and 20 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

What to Know About Pemgarda

By Staff
Tuesday, March 26, 2024 12:44 PM This week, the FDA granted emergency use authorization for Pemgarda, a new medication that protects higher-risk patients from COVID. Head to The New York Times for more on this latest update in COVID-related care.

How COVID-19 Treatments Affect Patients With IBD

By Staff
Tuesday, March 26, 2024 8:02 AM Inflammatory bowel disease (IBD) therapies for patients may need to be briefly halted during treatment for COVID-19, but it does not escalate IBD flares, with prior vaccination for COVID-19 helping reduce complications from the virus.

Medscape Placeholder

By Staff
Monday, March 25, 2024 8:02 AM